Novavax awaits regulatory decisions for its vaccine in the U.K., EU, Canada, New Zealand, India, and South Korea. It's already won Emergency Use Authorization (EUA) in Indonesia and the Philippines. The company expects to file for U.S. EUA before the end of this year. ( credited from the website The Motley Fool)
Is a good buy
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
4
举报
登录后可参与评论
暂无评论